Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

April 8, 2024

https://www.globenewswire.com/news-release/2024/04/08/2859187/0/en/Entera-Bio-Announces-Publication-of-Oral-PTH-1-34-Peptide-Tablets-EB613-Phase-2-Trial-Data-in-the-Journal-of-Bone-and-Mineral-Research.html

JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ:ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.